|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis显示文摘AIM To evaluate the therapeutic effects of ursodeoxycholic acid(UDCA) on autoimmune hepatitis(AIH).METHODS A total 136 patients who were diagnosed with AIH were included in our study. All of the patients underwent a liver biopsy, and had at least a probable diagnosis on the basis of either the revised scoring system or the simplified scores. Initial treatment included UDCA monotherapy(Group U, n = 48) and prednisolone(PSL) monotherapy(Group P, n = 88). Group U was further classified into two subgroups according to the effect of UDCA: Patients who had achieved remission induction with UDCA monotherapy and showed no sign of relapse(Subgroup U1, n = 34) and patients who additionally received PSL during follow-up(Subgroup U2, n = 14). We compared the clinical and histological findings between each groups, and investigated factorscontributing to the response to UDCA monotherapy.RESULTS In Group U, 34 patients(71%) achieved and maintained remission over 49(range: 8-90) mo(Subgroup U1) and 14 patients(29%) additionally received PSL(Subgroup U2) during follow-up. Two patients in Subgroup U2 achieved remission induction once but additionally required PSL administration because of relapse(15 and 35 mo after the start of treatment). The remaining 12 patients in Subgroup U2 failed to achieve remission induction during follow-up, and PSL was added during 7(range: 2-18) mo. Compared with Subgroup U2, Subgroup U1 had significantly lower alanine aminotransferase(ALT) levels at onset(124 IU/L vs 262 IU/L, P = 0.023) and a significantly higher proportion of patients with mild inflammation(A1) on histological examination(70.6% vs 35.7%, P = 0.025). When multivariate analysis was performed to identify factors contributing to the response to UDCA monotherapy, only a serum ALT level of 200 IU/L or lower was found to be associated with a significant difference(P = 0.013).CONCLUSION To prevent adverse events related to corticosteroids, UDCA monotherapy for AIH needs to be considered in patients with a serum ALT level of 200 IU/L or lower. | Yuichi Torisu Masanori Nakano Keiko Takano Ryo Nakagawa Chisato Saeki Atsushi Hokari Tomohisa Ishikawa Masayuki Saruta Mikio Zeniya | 2017 | World Journal of Hepatology2017，9，1： | 3 |
| 2 | Sal‐like protein 4 (SALL4), a stem cell biomarker in liver cancers显示文摘 | Tsunekazu Oikawa Akihide Kamiya Mikio Zeniya Hiromi Chikada Ahn Dong Hyuck Yuji Yamazaki Eliane Wauthier Hisao Tajiri Lance D. Miller Xin Wei Wang Lola M. Reid Hiromitsu Nakauchi | 2013 | Hepatology2013，，4： | 2 |
| 3 | Simplifi ed criteria for the diagnosis of autoimmune hepatitis显示文摘 | Hennes EM Zeniya M Czaja AJ | | Hepatology0，，： | 2 |
| 4 | Efficacy of MK615 for the treatment of patients with liver disorders显示文摘AIM:To investigate the hepatoprotective effect of MK615,a Japanese apricot extract,in an animal model,and its clinical therapeutic effect.METHODS:Wistar rats were administered physiological saline(4 mL/kg) or MK615 solution(4 mL/kg) for 7 d.On the sixth d,acute hepatic injury was induced by administering a single intraperitoneal injection(ip) of D-galactosamine hydrochloride(D-GalN)(600 mg/kg).Plasma levels of alanine aminotransferase(ALT) and aspartate aminotransferase(AST) were determined,and liver tissues were used for histopathological analysis.Fifty-eight patients with liver disorders [hepatitis C(n = 40),non-alcoholic fatty liver disease(n = 15),and autoimmune liver disease(n = 3)] were orally administered commercially available Misatol ME-containing MK615(13 g/d) daily for 12 wk.Blood and urine were sampled immediately before and 6 wk,12 wk,and 16 wk after the start of intake to measure various biochemical parameters.The percentage change in ALT and AST levels after 12 wk from the pre-intake baseline served as a primary endpoint.RESULTS:D-GalN effectively induced acute hepatic injury in the rats.At 48 h after the ip injection of D-GalN,the plasma levels of ALT(475.6 ± 191.5 IU/L vs 225.3 ± 194.2 IU/L,P < 0.05) and AST(1253.9 ± 223.4 IU/L vs 621.9 ± 478.2 IU/L,P < 0.05) in the MK615 group were significantly lower than the control group.Scattered single cell necrosis,loss of hepatocytes,and extensive inflammatory cell infiltration were observed in hepatic tissue samples collected from the control group.However,these findings were less pronounced in the group receiving MK615.At the end of the clinical study,serum ALT and AST levels were significantly decreased compared with pre-intake baseline levels from 103.5 ± 58.8 IU/L to 71.8 ± 39.3 IU/L(P < 0.05) and from 93.5 ± 55.6 IU/L to 65.5 ± 34.8 IU/L(P < 0.05),respectively.A reduction of ≥ 30% from the pre-study baseline ALT level was observed in 26(45%) of the 58 patients,while 25(43%) patients exhibited similar AST level reductions.The chronic hepatitis C group exhibited significant ALT and AST level reductions from 93.4 ± 51.1 IU/L to 64.6 ± 35.1 IU/L(P < 0.05) and from 94.2 ± 55.5 IU/L to 67.2 ± 35.6 IU/L(P < 0.05),respectively.A reduction of ≥ 30% from the pre-study baseline ALT level was observed in 20(50%) of the 40 patients.ALT levels in both the combined ursodeoxycholic acid(UDCA) treatment and the UDCA uncombined groups were significantly lower after Misatol ME administration.MK615 protected hepatocytes from D-GalN-induced cytotoxicity in rats.Misatol ME decreased elevated ALT and AST levels in patients with liver disorders.CONCLUSION:These results suggest that MK615 and Misatol ME are promising hepatoprotective agents for patients with liver disorders. | Atsushi Hokari Tomohisa Ishikawa Hisao Tajiri Takahide Matsuda Osamu Ishii Nobuyuki Matsumoto Chiaki Okuse Hideaki Takahashi Takeshi Kurihara Ko-ichi Kawahara Ikuro Maruyama Mikio Zeniya | 2012 | World Journal of Gastroenterology2012，18，31： | 2 |
| 5 | A Control Strategy to Reduce Steering Torque for Stationary Vehicles Equipped With EPS显示文摘 | Takayuki Kiful Noriyuki Inoue Usumu Zeniya | 1999 | SAE Paper1999，，： | 1 |
| 6 | Modified diagnostic criteria of drug-induced liver injury proposed by the international consensus meeting显示文摘 | Iwasa M Zeniya M Kumagi T | 2012 | Hepatogastroenterology2012，52，63： | 1 |
| 7 | Simplified criteria for thediagnosis of autoimmune hepatitis 显示文摘 | Hennes EM Zeniya M Czaja AJ | 2008 | Hepatology2008，48，1： | 1 |
| 8 | Modified diagnostic criteria of drug-induced liver injury proposed by the international consensus meeting显示文摘 | IWASE M ZENIYA M KUMAGI T | 2005 | Hepatogastroenterology2005，52，63： | 1 |
| 9 | A cross sectional study of primary biliary cirrhosis in Japan: ulizafion of clinical damwhen patients applied to receive public finaa cial aid显示文摘 | Sakauchi F Moil M Zeniya M | 2005 | J Epidemiol2005，15，3： | 1 |
| 10 | Background of the FIB - 4 Index in Japanese Non - Alcoholic Fatty Liver Disease 显示文摘 | Wada T Zeniya M | 2015 | Internal Medicine2015，54，2： | 1 |
| 11 | Simpliifed cirteira for the Diagnosis of autoimmune hepatitis显示文摘 | Hennes EM Zeniya M Czjaa AJ et a1 | 2008 | Hepatology2008，48，1： | 1 |
| 12 | Simplified criteria for thediagnosis of autoimmune hepatitis显示文摘 | Hennes EM Zeniya M Czaja AJ | 2008 | Hepatology2008，48，1： | 1 |
| 13 | International autoimmune hepatitis group, simplified criteria for the diagnosis of autoimmune hepatitis 显示文摘 | Hennes EM Zeniya M Czaja A J | 2008 | Hepatology2008，48，1： | 1 |
| 14 | Present status of autoimmune hepatitis in Japan: a nationwide survey 显示文摘 | ABE M MASHIBA T ZENIYA M | 2011 | J Gastroenterol2011，46，9： | 1 |
| 15 | Modified diagnostic criteria of drug-induced liver injury proposed by the international consensus meeting显示文摘 | Iwasa M Zeniya M Kumagi T | 2005 | Hepatogastroenterology2005，52，63： | 1 |
| 16 | Simplified criteria for the diagnosis of autoimmune hepatitis 显示文摘 | HENNES EM ZENIYA M CZAJA A J | 2008 | Hepatology2008，48，1： | 1 |
| 17 | Simplified criteria for the diagnosis ofautoimmune hepatitis显示文摘 | Hennes EM Zeniya M Czaja AJ | 2008 | Hepatology2008，48，1： | 1 |
| 18 | Usefulness of combined application of double filtration plasmapheresis and twice-daily injections of interferon-β in hemodialysis patients with hepati- tis C virus genotype lb infection and a high viral load显示文摘 | Zeniya M Nakano M Saeki C | 2014 | Hepatol Res2014，44，10： | 1 |
| 19 | A cross- sectional study of primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid显示文摘 | Sakauchi F Moil M Zeniya M | 2005 | J Epidemiol2005，15，1： | 1 |
| 20 | Immunogenetic background of hepatitis B virus infection and autoimmune hepatitis in Japan显示文摘 | Zeniya M Watansbe F Aixaza Y | 1993 | Gastroenterol Jpn1993，28，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员